Abstract | PURPOSE: DESIGN: Phase II, multicenter, masked, randomized clinical trial. METHODS: RESULTS: At month 12, patients lost a mean of 15.7 letters and 11.4 letters from baseline in the standard and delayed light groups, respectively (P = .38). Twelve (52%) of 23 patients in the standard light group and 11 (42%) of 26 in the delayed light group lost at least 15 letters of visual acuity (P = .57). CONCLUSIONS: There were no statistically significant differences between verteporfin therapy using the delayed light regimen of 30 minutes or the standard light regimen of 15 minutes in eyes with occult with no classic CNV.
|
Authors | Philip J Rosenfeld, David S Boyer, Neil M Bressler, Gary Fish, W Sanderson Grizzard, Yong Hao, Peter Hnik, Henry L Hudson, Lawrence Singerman, Jason S Slakter, VALIO Study Group |
Journal | American journal of ophthalmology
(Am J Ophthalmol)
Vol. 144
Issue 6
Pg. 970-972
(Dec 2007)
ISSN: 0002-9394 [Print] United States |
PMID | 18036873
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Coloring Agents
- Photosensitizing Agents
- Porphyrins
- Verteporfin
- Indocyanine Green
|
Topics |
- Choroidal Neovascularization
(drug therapy, etiology)
- Coloring Agents
- Fluorescein Angiography
- Humans
- Indocyanine Green
- Macular Degeneration
(complications)
- Photochemotherapy
(methods)
- Photosensitizing Agents
(therapeutic use)
- Porphyrins
(therapeutic use)
- Retreatment
- Time Factors
- Treatment Outcome
- Verteporfin
- Visual Acuity
|